Media headlines about TG Therapeutics (NASDAQ:TGTX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TG Therapeutics earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.7951581758772 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
TG Therapeutics (TGTX) traded down $0.20 during trading hours on Wednesday, reaching $8.05. The company had a trading volume of 1,162,700 shares, compared to its average volume of 1,542,507. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. equities analysts expect that TG Therapeutics will post -1.86 EPS for the current fiscal year.
TGTX has been the topic of a number of recent research reports. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. SunTrust Banks reaffirmed a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price objective (up previously from $18.00) on shares of TG Therapeutics in a research report on Tuesday, November 14th. Finally, B. Riley initiated coverage on TG Therapeutics in a research report on Friday, December 1st. They set a “buy” rating and a $21.50 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $25.50.
ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/13/tg-therapeutics-tgtx-given-news-impact-score-of-0-21.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.